Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Precision Promise Platform Trial for Metastatic Pancreatic Cancer

Next Previous
Trial Profile

Precision Promise Platform Trial for Metastatic Pancreatic Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 08 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canakinumab (Primary) ; Nadunolimab (Primary) ; Pamrevlumab (Primary) ; Pelareorep (Primary) ; Racemetyrosine (Primary) ; Spartalizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Methoxsalen; Oxaliplatin; Paclitaxel; Phenytoin; Sirolimus
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PanCAN-Precision-PromiseSM; Precision Promise

    • Most Recent Events

    • 05 Feb 2024 According to a FibroGen media release, company announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM ET to include information on the mechanism of action of pamrevlumab in Phase 1/2 trial, Precision Promise Phase 2/3 trial and LAPIS Phase 3 trial.
    • 25 Jan 2024 According to a FibroGen media release, Pamrevlumab is the first experimental arm to meet its required threshold for graduation in the seamless Phase 2/3 adaptive platform trial and pamrevlumab arm of the study completed Stage 2 of the trial in January 2024.
    • 25 Jan 2024 According to a FibroGen media release, company announced graduation and completion of the pamrevlumab experimental arm. Topline data from this registration study is anticipated in the second quarter of 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top